|
Market Cap (24-Jun) $27,342,400 (1,032nd) |
Close (30-Jun) $0.008 |
Volume (30-Jun) 285,280 |
Shortsold (12-Dec) 6,497 (0.00%) (681st) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.09 |
EX1 released this announcement to the ASX on 31 August 2022, 8:08. The announcement is not marked as price sensitive, and is 36 page(s) in length and 837.81kb in size.
You can view all announcements from EX1 and see how they appear on a price chart on the announcements page.
At the date of this announcement, EX1 was 0.012% short sold according to ASIC data. It was ranked the 605th most shorted stock on the ASX. It remains ranked 681st as of the latest reported data (12 December 2022).
| Other Recent Announcements from EX1 | |
|---|---|
| Initial Director's Interest Notice - MD | 22 June 2023, 11:52 |
| Change of Director's Interest Notice - CB | 22 June 2023, 11:51 |
| Final Director's Interest Notice - JW | 22 June 2023, 11:50 |
| Appendix 4G and Corporate Governance Statement | 31 August 2022, 8:08 |
| Quarterly Activities Report and Appendix 4C | 29 July 2022, 8:02 |
| EX1 to receive a further $0.48m in prepaid R&D Tax Incentive | 28 July 2022, 17:56 |
| EX1 to Receive over $2.7m in Prepaid R&D Tax Incentive Claim | 16 June 2022, 14:19 |
You must be logged in to post a reply.
Exopharm 